{"entity":{"id":"paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020","kind":"paper","name":"Marginal zone lymphomas: ESMO clinical practice guidelines","aka":[],"tldr":"The ESMO guideline for marginal zone lymphomas sets out the treatment of gastric and non-gastric extranodal, splenic and nodal forms, including antibiotic eradication, low-dose radiotherapy, watch and wait, rituximab-based therapy and BTK inhibitors at relapse.","summary":"Evidence-based guideline covering diagnosis, staging, and first-line and relapsed treatment of extranodal (MALT), splenic and nodal marginal zone lymphomas, including the role of infectious agents (Helicobacter pylori, hepatitis C), involved-site radiotherapy, chemoimmunotherapy and novel agents.","asOf":"2026-09-17","links":[{"label":"Ann Oncol 2020","url":"https://doi.org/10.1016/j.annonc.2019.10.010"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31912792/"}],"tags":[],"related":[],"cancers":["marginal-zone-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2019.10.010","pmid":"31912792","authors":"Zucca E, Arcaini L, Buske C, et al.","paperType":"guideline","findings":[],"whatItMeans":"The site-specific and stage-specific approach on the marginal zone lymphoma page follows this guideline.","caveats":["Randomised evidence is limited for most decisions in these indolent lymphomas."],"changedPractice":true},"route":"/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/","neighbours":{"cancer":[{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"}],"journal":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/"}]}}